HSBC trading unit hit by $355m of XVA costs in H1

Adverse adjustments to the valuation of non-cleared derivatives (XVAs) at HSBC continued to sap earnings over the three months to end-June. Over the first six months of the year, credit valuation adjustments (CVA) and funding valuation adjustments (FVA) have lopped a combined $355 million off of income. 

The hit was recorded at the UK firm’s global banking and markets (GB&M) division, and was equivalent in size to 4% of first-half revenues. Over the half-year to June 2019, CVA and FVA

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: